Eagle Swats More Vasopressin Hurdles As Petition And Injunction Are Denied

FDA Intends To Refer Par Citizen Petition To US Federal Trade Commission

 
• By Dean Rudge

In a clean sweep for Eagle Pharmaceuticals, following its recent approval for the first generic version of Par’s Vasostrict, the ANDA sponsor has seen defeated a Par citizen petition and dodged injunctive action launched by the Endo subsidiary.

Sign outside of FDA's headquarters in White Oak, MD
Par's petition did not raise "valid or scientific regulatory issues" • Source: Alamy

More from Generics

More from Products